Abstract
Melanoma has a very high propensity to metastasize to the central nervous system (CNS), including the brain and leptomeninges. Neurosurgery and stereotactic radiosurgery represent valuable and effective modalities and have been the mainstay of therapy for melanoma metastatic to the brain. Integration of these modalities with systemic therapy in a multidisciplinary approach is critical for the management of this complex and devastating complication of metastatic melanoma. Advances in systemic therapy recently led to clinical benefit for patients with melanoma brain metastases (MBM), with high response rates observed for combination targeted therapies and combination immune checkpoint blocking antibodies. However, the duration of response seems to be more limited for targeted therapy than for the durable responses induced by immunotherapy. The underlying biological tenets of response and resistance to targeted and immune therapies are thoroughly discussed in this chapter. We also review the challenges of measuring clinical benefit and offer a perspective for future drug development in this unique patient population.
This is a preview of subscription content, log in via an institution to check access.
References
Absinta M, Ha SK, Nair G, Sati P, Luciano NJ, Palisoc M, et al (2017) Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife 6. https://doi.org/10.7554/eLife.29738
Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101–2107. https://doi.org/10.1200/jco.2004.11.044
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB et al (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681–1696. https://doi.org/10.1016/j.cell.2015.05.044
Alrehaili AA, Lee JY, Bakhuraysah MM, Kim MJ, Aui PM, Magee KA et al (2018) Nogo receptor expression in microglia/macrophages during experimental autoimmune encephalomyelitis progression. Neural Regen Res 13(5):896–907. https://doi.org/10.4103/1673-5374.232488
Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH et al (2015) Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 72(1):59–70. https://doi.org/10.1016/j.jaad.2014.09.029
Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16(1):1–13. https://doi.org/10.1016/j.nbd.2003.12.016
Banks WA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 9(Suppl 1):S3. https://doi.org/10.1186/1471-2377-9-S1-S3
Beckford Vera DR, Smith CC, Bixby LM, Glatt DM, Dunn SS, Saito R et al (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13(3):e0193832. https://doi.org/10.1371/journal.pone.0193832
Berghoff AS, Preusser M (2018) Role of the blood-brain barrier in metastatic disease of the central nervous system. Handb Clin Neurol 149:57–66. https://doi.org/10.1016/B978-0-12-811161-1.00004-9
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596–599. https://doi.org/10.1038/nature09454. http://www.nature.com/nature/journal/v467/n7315/abs/nature09454.html#supplementary-information
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213–5219. https://doi.org/10.1158/0008-5472.CAN-10-0118
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5(11):1164–1177. https://doi.org/10.1158/2159-8290.CD-15-0369
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology 15(10):1429–1437. https://doi.org/10.1093/neuonc/not114
Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D et al (2014) Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 20(21):5527–5536. https://doi.org/10.1158/1078-0432.CCR-14-1027
Budman DR, Camacho E, Wittes RE (1978) The current causes of death in patients with malignant melanoma. Eur J Cancer 14(4):327–330. https://www.ncbi.nlm.nih.gov/pubmed/648555
Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M et al (2018) Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in neuro-oncology brain metastases working group. Lancet Oncol 19(1):e20–e32. https://doi.org/10.1016/s1470-2045(17)30693-9
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. https://doi.org/10.1056/NEJMoa1103782
Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubberhorst B et al (2014) Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20(21):5337–5346. https://doi.org/10.1158/1078-0432.ccr-13-3003
Chmielowski B (2018) How should we assess benefit in patients receiving checkpoint inhibitor therapy? J Clin Oncol 36(9):835–836. https://doi.org/10.1200/jco.2017.76.9885
Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G et al (2015) AKT1 activation promotes development of melanoma metastases. Cell Rep 13(5):898–905. https://doi.org/10.1016/j.celrep.2015.09.057
Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A et al (2016) Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res 4(3):179–182. https://doi.org/10.1158/2326-6066.CIR-15-0160
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522–2529. https://doi.org/10.1200/jco.2011.41.2452
Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A et al (2013) BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2(10):e26615. https://doi.org/10.4161/onci.26615
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr et al (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544–552. https://doi.org/10.1038/ng.356
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954. https://doi.org/10.1038/nature00766
Davies MA (2012) The role of the PI3K-AKT pathway in melanoma. Cancer J 18(2):142–147
Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696. https://doi.org/10.1002/cncr.25634
Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A et al (2017) Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863–873. https://doi.org/10.1016/S1470-2045(17)30429-1
Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN et al (2009) Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15(24):7538–7546. https://doi.org/10.1158/1078-0432.CCR-09-1985
Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13(9):879–886. https://doi.org/10.1016/S1470-2045(12)70324-8
DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, Kaur G et al (2018) The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology 7(7):e1448329. https://doi.org/10.1080/2162402X.2018.1448329
Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y et al (2013) PTEN functions as a melanoma tumor suppressor by promoting host immune response (original article). Oncogene. https://doi.org/10.1038/onc.2013.409
Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S et al (2014) Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med 2014:417913. https://doi.org/10.1155/2014/417913
Du Four S, Wilgenhof S, Duerinck J, Michotte A, Van Binst A, De Ridder M et al (2012) Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 48(16):3045–3051. https://doi.org/10.1016/j.ejca.2012.05.016
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with <em>BRAF</em>−mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603–615. https://doi.org/10.1016/S1470-2045(18)30142-6
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al (2006) Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95(5):581–586. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16880785
Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 33(12):579–589. https://doi.org/10.1016/j.it.2012.07.004
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901. http://linkinghub.elsevier.com/retrieve/pii/S0140673612603985
Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P et al (2017) Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neuro-Oncol 133(3):595–602. https://doi.org/10.1007/s11060-017-2470-4
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. https://doi.org/10.1056/NEJMoa1210093
Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D (2008) Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 586(7):1937–1949. https://doi.org/10.1113/jphysiol.2007.146852
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1231. https://doi.org/10.1158/1078-0432.CCR-12-1630
Furuse M, Nonoguchi N, Kawabata S, Miyatake S, Kuroiwa T (2015) Delayed brain radiation necrosis: pathological review and new molecular targets for treatment. Med Mol Morphol 48(4):183–190. https://doi.org/10.1007/s00795-015-0123-2
Garcia-Martin AB, Zwicky P, Gruber T, Matti C, Moalli F, Stein JV, et al (2018) VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption. J Cereb Blood Flow Metab 271678x18775887. https://doi.org/10.1177/0271678x18775887
Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312. https://doi.org/10.1200/jco.2006.10.0677
Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W (2016) Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol 27(6):1138–1142. https://doi.org/10.1093/annonc/mdw134
Glitza IC, Guha-Thakurta N, D’Souza NM, Amaria RN, McGovern SL, Rao G et al (2017) Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res 27(6):580–584. https://doi.org/10.1097/CMR.0000000000000389
Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A et al (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283. https://doi.org/10.1136/esmoopen-2017-000283
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983. https://doi.org/10.1016/S1470-2045(16)30053-5
Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD et al (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736–8747. https://doi.org/10.1158/0008-5472.CAN-10-0902
Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA et al (2002) Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25(1):82–87
Harazin A, Bocsik A, Barna L, Kincses A, Varadi J, Fenyvesi F et al (2018) Protection of cultured brain endothelial cells from cytokine-induced damage by alpha-melanocyte stimulating hormone. PeerJ 6:e4774. https://doi.org/10.7717/peerj.4774
Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27(17):2823–2830. https://doi.org/10.1200/JCO.2007.15.7636
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. https://doi.org/10.1016/S0140-6736(12)60868-X
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J et al (2018) Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 36(9):850–858. https://doi.org/10.1200/jco.2017.75.1644
Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N et al (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557–561. https://doi.org/10.1038/ncponc1183
Holfort SK, Lindegaard J, Isager P, Prause JU, Heegaard S (2009) CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation. Br J Ophthalmol 93(5):641–644. https://doi.org/10.1136/bjo.2008.145664
How J, Mann J, Laczniak AN, Baggstrom MQ (2017) Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature. Clin Lung Cancer 18(4):354–363. https://doi.org/10.1016/j.cllc.2017.01.013
Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A et al (2015) The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer 136(6):1296–1307. https://doi.org/10.1002/ijc.29090
Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M et al (2012) The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int J Cancer 131(5):1071–1082. https://doi.org/10.1002/ijc.27324
Ji RR, Xu ZZ, Gao YJ (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13(7):533–548. https://doi.org/10.1038/nrd4334
Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS et al (2015) PLEKHA5 as a biomarker and potential mediator of melanoma brain metastasis. Clin Cancer Res 21(9):2138–2147. https://doi.org/10.1158/1078-0432.ccr-14-0861
Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D et al (2017) The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anti-Cancer Drugs 28(6):669–675. https://doi.org/10.1097/cad.0000000000000497
Kawakami N, Lassmann S, Li Z, Odoardi F, Ritter T, Ziemssen T et al (2004) The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med 199(2):185–197. https://doi.org/10.1084/jem.20031064
Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR et al (2011) Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13(3):286–298. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21390191
Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M (2004) T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A 101(21):8180–8185. https://doi.org/10.1073/pnas.0402268101
Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S et al (2017) CCR4 is a determinant of melanoma brain metastasis. Oncotarget 8(19):31079–31091. https://doi.org/10.18632/oncotarget.16076
Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T et al (2018) Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37(1):52–60. https://doi.org/10.1200/JCO.18.00204
Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M et al (2015) Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21(13):3052–3060. https://doi.org/10.1158/1078-0432.CCR-14-3073
Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227–233. https://doi.org/10.3171/2012.5.JNS111929
Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neuro-Oncol 125(1):149–156. https://doi.org/10.1007/s11060-015-1881-3
Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37. https://doi.org/10.1016/j.ctrv.2016.11.013
Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE (2014) Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res 74(15):4122–4132. https://doi.org/10.1158/0008-5472.can-14-0464
Kunis G, Baruch K, Rosenzweig N, Kertser A, Miller O, Berkutzki T et al (2013) IFN-gamma-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair. Brain 136(Pt 11):3427–3440. https://doi.org/10.1093/brain/awt259
Laack NN, Brown PD (2004) Cognitive sequelae of brain radiation in adults. Semin Oncol 31(5):702–713. https://www.ncbi.nlm.nih.gov/pubmed/15497124
Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG et al (2015) Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212(4):481–495. https://doi.org/10.1084/jem.20141656
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M et al (2014a) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876. https://doi.org/10.1056/NEJMoa1408868
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M et al (2014b) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876. https://doi.org/10.1056/NEJMoa1408868
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214–218. https://doi.org/10.1038/nature12213
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9072974
Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270–e278. https://doi.org/10.1016/S1470-2045(15)70057-4
Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R et al (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 14(10):e407–e416. https://doi.org/10.1016/s1470-2045(13)70308-5
Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H et al (2010) Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12(9):748–754. http://www.ncbi.nlm.nih.gov/pubmed/20824051
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1–3):3–26. http://www.ncbi.nlm.nih.gov/pubmed/11259830
Liu Z, Poiret T, Persson O, Meng Q, Rane L, Bartek J Jr et al (2018) NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma. Cancer Immunol Immunother 67(2):237–246. https://doi.org/10.1007/s00262-017-2066-z
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672–681. https://doi.org/10.1016/s1470-2045(18)30139-6
Long GV, Grob JJ, Nathan PD, Ribas A, Robert C, Schadendorf D et al (2016) Pooled analysis of individual patient data across dabrafenib and trametinib combination therapy randomised trials to identify factors that predict response, progression, and long-term outcomes. Lancet Oncol 17(12):1743–1754
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095. http://linkinghub.elsevier.com/retrieve/pii/S147020451270431X
Luke JJ, Flaherty KT, Ribas A, Long GV (2017a) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463–482. https://doi.org/10.1038/nrclinonc.2017.43
Luke JJ, Flaherty KT, Ribas A, Long GV (2017b) Targeted agents and immunotherapies: optimizing outcomes in melanoma (review). Nat Rev Clin Oncol 14(8):463–482. https://doi.org/10.1038/nrclinonc.2017.43
Marchan EM, Sheehan J (2012) Stereotactic radiosurgery of brain metastasis from melanoma. Prog Neurol Surg 25:176–189. https://doi.org/10.1159/000331191
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465. https://doi.org/10.1016/S1470-2045(12)70090-6
Mark KS, Trickler WJ, Miller DW (2001) Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 297(3):1051–1058. https://www.ncbi.nlm.nih.gov/pubmed/11356928
McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF et al (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28(3):634–641. https://doi.org/10.1093/annonc/mdw641
McCarthy DP, Richards MH, Miller SD (2012) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol 900:381–401. https://doi.org/10.1007/978-1-60761-720-4_19
McKenzie BA, Mamik MK, Saito LB, Boghozian R, Monaco MC, Major EO et al (2018) Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc Natl Acad Sci U S A 115(26):E6065–E6074. https://doi.org/10.1073/pnas.1722041115
McKinney AJ, Holmen SL (2011) Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin J Cancer 30(3):153–162. http://www.ncbi.nlm.nih.gov/pubmed/21352692
McQuade J, Davies MA (2015) Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag 2(3):241–254. https://doi.org/10.2217/mmt.15.18
Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW (2016) The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29(5):590–597. https://doi.org/10.1111/pcmr.12498
Megra BW, Eugenin EA, Berman JW (2018) Inflammatory mediators reduce surface PrP(c) on human BMVEC resulting in decreased barrier integrity. Lab Investig. https://doi.org/10.1038/s41374-018-0090-z
Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA et al (2016) Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96(5):1060–1069. https://doi.org/10.1016/j.ijrobp.2016.08.039
Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F et al (2016) Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys 95(4):1142–1148. https://doi.org/10.1016/j.ijrobp.2016.03.013
Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T et al (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66(13):6546–6552. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16818626
Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344(3):655–664. https://doi.org/10.1124/jpet.112.201475
Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR (2003) Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 63(14):4021–4027. https://www.ncbi.nlm.nih.gov/pubmed/12874001
Moshe A, Izraely S, Sagi-Assif O, Prakash R, Telerman A, Meshel T et al (2018) Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis. Clin Exp Metastasis. https://doi.org/10.1007/s10585-018-9891-0
Nathanson KL, Martin A-M, Wubbenhorst B, Greshock J, Letrero R, D’Andrea K et al (2013) Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res 19(17):4868–4878. https://doi.org/10.1158/1078-0432.ccr-13-0827
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973–977. https://doi.org/10.1038/nature09626. http://www.nature.com/nature/journal/v468/n7326/abs/nature09626.html#supplementary-information
Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A et al (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2(1):76–85. https://doi.org/10.1002/cam4.50
Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N et al (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161(3):653–660. https://doi.org/10.1083/jcb.200302070
Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C et al (2017) Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. Oncotarget 8(61):103671–103681. https://doi.org/10.18632/oncotarget.22110
Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen A, Munko AC et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71(7):2750–2760. https://doi.org/10.1158/0008-5472.CAN-10-2954
Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S et al (2017) Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 116(12):1558–1563. https://doi.org/10.1038/bjc.2017.142
Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB et al (2011) Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 108(42):17456–17461. https://doi.org/10.1073/pnas.1114210108
Patel KR, Burri SH, Asher AL, Crocker IR, Fraser RW, Zhang C et al (2016a) Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery 79(2):279–285. https://doi.org/10.1227/NEU.0000000000001096
Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ et al (2016b) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26(4):387–394. https://doi.org/10.1097/CMR.0000000000000268.
Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH et al (2017) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40(5):444–450. https://doi.org/10.1097/COC.0000000000000199
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT et al (2016) Loss of PTEN promotes resistance to T-cell mediated immunotherapy. Cancer Discov 6(2):201–216
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1):19–20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12447372
Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC (2015) Mast cells in meningiomas and brain inflammation. J Neuroinflammation 12:170. https://doi.org/10.1186/s12974-015-0388-3
Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W et al (2018) STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. https://doi.org/10.1038/s41591-018-0044-4
Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neuro-Oncol 118(1):109–116. https://doi.org/10.1007/s11060-014-1400-y
Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368(14):1365–1366. https://doi.org/10.1056/NEJMc1302338
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39. https://doi.org/10.1056/NEJMoa1412690
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894. https://doi.org/10.1200/JCO.2014.56.2736
Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A et al (2010) Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20(3):247–250. https://doi.org/10.1097/CMR.0b013e3283364a37
Seifert H, Hirata E, Gore M, Khabra K, Messiou C, Larkin J et al (2016) Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res 29(1):92–100. https://doi.org/10.1111/pcmr.12424
Seo JW, Tavare R, Mahakian LM, Silvestrini MT, Tam S, Ingham ES et al (2018) CD8+ T-cell density imaging with 64Cu-labeled cys-diabody informs immunotherapy protocols. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-0261
Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A et al (2015) The genetic evolution of melanoma from precursor lesions. N Engl J Med 373(20):1926–1936. https://doi.org/10.1056/NEJMoa1502583
Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA et al (2018) Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med 215(3):895–910. https://doi.org/10.1084/jem.20171818
Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2(6):899–906. https://doi.org/10.1002/cam4.140
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356–362. https://doi.org/10.1038/ng0497-356
Stephan AH, Barres BA, Stevens B (2012) The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 35:369–389. https://doi.org/10.1146/annurev-neuro-061010-113810
Sun BL, Wang LH, Yang T, Sun JY, Mao LL, Yang MF et al (2018) Lymphatic drainage system of the brain: a novel target for intervention of neurological diseases. Prog Neurobiol 163–164:118–143. https://doi.org/10.1016/j.pneurobio.2017.08.007
Syed ON, Mandigo CE, Killory BD, Canoll P, Bruce JN (2012) Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci 19(7):1016–1021. https://doi.org/10.1016/j.jocn.2011.10.008
Takashima Y, Kawaguchi A, Kanayama T, Hayano A, Yamanaka R (2018) Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget 9(27):19065–19078. https://doi.org/10.18632/oncotarget.24897
Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7:77. https://doi.org/10.1186/1748-717X-7-77
Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB et al (2016) An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res 76(1):73–82. https://doi.org/10.1158/0008-5472.Can-15-1707
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722–730. https://doi.org/10.1056/NEJMoa1805453
Tazi K, Hathaway A, Chiuzan C, Shirai K (2015) Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4(1):1–6. https://doi.org/10.1002/cam4.315
Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR (2017) Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget 8(48):83734–83744. https://doi.org/10.18632/oncotarget.19634
Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting (review). Nat Rev Cancer 15(1):7–24. https://doi.org/10.1038/nrc3860. http://www.nature.com/nrc/journal/v15/n1/abs/nrc3860.html#supplementary-information
Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH (2018) Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep 8(1):8267. https://doi.org/10.1038/s41598-018-26636-6
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE et al (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31(14):1767–1774. https://doi.org/10.1200/jco.2012.44.7888
Tsao M, Xu W, Sahgal A (2012a) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118(9):2486–2493. https://doi.org/10.1002/cncr.26515
Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N et al (2012b) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869. https://doi.org/10.1002/14651858.CD003869.pub3
Vanhaesebroeck B, Stephens L, Hawkins P (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13(3):195–203. https://doi.org/10.1038/nrm3290
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6):683–695. http://www.sciencedirect.com/science/article/B6WWK-51P9GXT-H/2/131b9043fd8ca3543ef156e388934313
Walentynowicz KA, Ochocka N, Pasierbinska M, Wojnicki K, Stepniak K, Mieczkowski J et al (2018) In search for reliable markers of glioma-induced polarization of microglia. Front Immunol 9:1329. https://doi.org/10.3389/fimmu.2018.01329
Walsh JT, Hendrix S, Boato F, Smirnov I, Zheng J, Lukens JR et al (2015) MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J Clin Invest 125(2):699–714. https://doi.org/10.1172/JCI76210
Wang Y, Wang E, Pan L, Dai J, Zhang N, Wang X et al (2014) A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neuro-Oncol 119(2):369–376. https://doi.org/10.1007/s11060-014-1488-0
Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B et al (1998) Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 4(7):808–813. http://www.ncbi.nlm.nih.gov/pubmed/9662372
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356. https://doi.org/10.1056/NEJMoa1709684
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE et al (2006) Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188–3196. https://doi.org/10.1158/0008-5472.CAN-05-2674
Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB et al (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31(4):248–258. https://doi.org/10.1038/onc.2011.250
Yoshida Y, Sejimo Y, Kurachi M, Ishizaki Y, Nakano T, Takahashi A (2018) X-ray irradiation induces disruption of the blood-brain barrier with localized changes in claudin-5 and activation of microglia in the mouse brain. Neurochem Int. https://doi.org/10.1016/j.neuint.2018.03.002
Zhou X-P, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157(4):1123–1128. http://ajp.amjpathol.org/cgi/content/abstract/157/4/1123
Zhuang H, Zheng Y, Wang J, Chang JY, Wang X, Yuan Z et al (2016) Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget 7(7):7773–7779. https://doi.org/10.18632/oncotarget.6532
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM et al (2017) Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. J Immunother Cancer 5(1):77. https://doi.org/10.1186/s40425-017-0278-6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Margolin, K., Davies, M., Kluger, H., Tawbi, H. (2019). Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-46029-1_65-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-46029-1_65-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46029-1
Online ISBN: 978-3-319-46029-1
eBook Packages: Springer Reference MedicineReference Module Medicine